Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Loses External Relations Head Skladany: Focus Included Staff Recruiting

Executive Summary

FDA Associate Commissioner for External Relations Linda Skladany is leaving the agency April 18

You may also be interested in...



FDA “Chief Messaging Officer” Pitts Will Centralize Agency Communications

FDA Associate Commissioner for External Relations Peter Pitts will coordinate FDA's communications within the commissioner's office and across the agency's centers

FDA “Chief Messaging Officer” Pitts Will Centralize Agency Communications

FDA Associate Commissioner for External Relations Peter Pitts will coordinate FDA's communications within the commissioner's office and across the agency's centers

FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford

FDA's difficulty in staffing the Reproductive Health Drugs Advisory Committee is a result of a "broken process," Acting Commissioner Lester Crawford told a Women in Government Relations luncheon in Washington, D.C. Oct. 11

UsernamePublicRestriction

Register

PS041474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel